Vichem Chemie Research Ltd

What Vichem Chemie Research Ltd does

Vichem Chemie Research Ltd is a privately held Hungarian contract research organization (CRO) specializing in kinase inhibitor drug discovery, branded as 'The Kinase Inhibitor Company.' Founded in 1990 and headquartered in Budapest with offices in Veszprém, the company serves pharmaceutical companies, biotechnology firms, and academic institutions through bespoke drug discovery projects spanning hit finding, assay development, hit-to-lead optimization, custom synthesis, and process development.

The company's core technology is built around its proprietary Nested Chemical Library™ (NCL), a curated collection of more than 17,000 chemical entities organized around 110+ core structures and 600+ scaffolds covering 160+ validated kinase targets. This library is supplemented by the Allosteric Library (AL) for non-ATP-competitive targets, the Tool Compound Library (TCL) for probe generation, and the DriverHit Library® (DHL) covering 114 cancer driver genes for personalized combination therapy development. The platform integrates medicinal chemistry, computational modeling via Schrödinger software, and a synthetic toolkit exceeding 27,000 protocols. Vichem has produced 43 patent families, advanced the lead candidate Otviciclib (a multi-CDK inhibitor for multiple myeloma) in collaboration with the Medical University of Innsbruck, and developed selective FLT3 and PI3K-AKT-mTOR pathway inhibitors.

Vichem operates a multi-stream revenue model combining fee-for-service contract research, compound library licensing and sales, and EU/national research grant funding (FP6, FP7, Horizon Europe, KTIA, NRDI). The company does not publicly disclose pricing, operating on quote-based bespoke engagements. Go-to-market relies on direct enterprise engagement with pharma R&D departments, biotech drug programs, and academic research consortia, supported by peer-reviewed publication output and a scientific advisory board. The customer base spans strategic partners including Max Planck Institute, Semmelweis University, Institut Pasteur, EPFL, A*STAR, Oncotyrol, ViroStatics, and named pharma relationships with Bayer, Pfizer, Johnson & Johnson, and Galapagos.

Name

Vichem Chemie Research Ltd

Legal name

Vichem Chemie Research Ltd

Website

https://vichemchemie.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

11–50 employees

Short description

Vichem Chemie Research Ltd is a Hungarian contract research organization specializing in kinase inhibitor drug discovery, serving pharmaceutical companies, biotechnology firms, and academic institutions through proprietary compound libraries and integrated medicinal chemistry services.

Ownership category

akta.pro rank

Product category

Contract Research / Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Kinase inhibitor drug discovery
• Medicinal chemistry services
• Compound library synthesis
• Contract research organization
• Hit to lead optimization

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Contract Research Services: Project-based fee-for-service contracts providing drug discovery services to pharma companies, biotech firms, and academic institutions. Services include hit finding, assay development, custom synthesis, process optimization, and analytical services. Revenue is earned through negotiated project fees.
2. Compound Library Licensing / Sales: Sale or licensing of proprietary compound library collections (NCL, AL, TCL, DHL) to pharmaceutical and biotech clients for their internal drug discovery programs. Compounds are provided as solid form or DMSO solutions in various plate formats.
3. EU and National Research Grants: Vichem participates as a consortium partner in EU Framework Programme grants (FP6, FP7, Horizon Europe) and Hungarian national grants (KTIA, NRDI). Grant funding supports specific R&D projects and provides non-dilutive capital for drug development programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Vichem Chemie Research Ltd is a Hungarian contract research organization that delivers kinase inhibitor drug discovery services for pharmaceutical and biotechnology clients. Its core offer includes proprietary compound libraries (Nested Chemical Library, Allosteric Library, Tool Compound Library, DriverHit Library), integrated hit finding, assay development, hit-to-lead optimization, custom synthesis, scale-up process development, fluorescent labeling, and NMR analytical services, taking clients' biological targets through to patentable lead molecules.

Product overview

Vichem Chemie Research Ltd is a contract research organization specializing in kinase inhibitor drug discovery, operating as 'The Kinase Inhibitor Company.' Their portfolio is built around proprietary compound libraries—the Nested Chemical Library™ (NCL) platform with its sub-libraries (CVL, EVL, ML), the Allosteric Library (AL), Tool Compound Library (TCL), and the DriverHit Library® (DHL) for cancer combination therapies—alongside integrated drug discovery services including hit finding, assay development, hit-to-lead optimization, custom synthesis, process development, fluorescent labeling, and NMR analytics. The company maintains active R&D programs in FLT3 inhibitors for AML, CDK9 inhibitors for HIV, Otviciclib for multiple myeloma and solid tumors, and collaborates with academic and pharmaceutical partners on tuberculosis, fibrosis, and retinopathies through various EU and national grants.

Differentiator

Problem solved

Functional benefit

Products and services

• Nested Chemical Library™ (NCL) A proprietary compound library for hit and lead finding in kinase inhibitor drug design, comprising more than 17,000 chemical entities organized around more than 110 core structures and more than 600 scaffolds targeting more than 160 validated kinase targets. Provided to pharmaceutical and biotech clients for screening campaigns.
• Chemical Validation Library (CVL) A sub-library of more than 400 proven kinase inhibitors used for in vitro or in vivo target validation, enabling chemical validation of novel kinase targets for client drug discovery programs.
• Extended Validation Library (EVL) A sub-library containing more than 2,000 compounds including CVL compounds and closest patentable analogues, used for hit finding when robust screening assays are unavailable.
• Master Library (ML) An extended library of approximately 15,000 compounds filtered for ADMET properties, druglikeness, and patentability, including novel compounds and analog structures around CVL and EVL.
• Allosteric Library (AL) A library of more than 2,000 compounds built around 40+ published allosteric enzyme inhibitors and modulators, including Type II (DFG-out), Type III (exclusive allosteric pocket), and Type IV (distant site) kinase inhibitors and kinase activation inhibitors.
• Tool Compound Library (TCL) A collection of more than 300 modified kinase inhibitors equipped with primary amine, carboxyl, acetylene, or azide linkers, enabling fluorescent dye labeling for binding kinetics, affinity chromatography for target identification, and targeted delivery when bound to carriers.
• DriverHit Library® (DHL) A small molecule library targeting 114 cancer driver genes (57 oncogenes and 57 tumor suppressor genes), containing 2,926 compounds including 386 reference compounds, with 273 clinical reference compounds covering 96 drivers. Designed for personalized combination cancer therapies.
• Kinase Inhibitor Building Blocks (KIBB) A catalog of 1,325 unique intermediates in 23 compound families applicable for the synthesis of different highly potent kinase inhibitors.
• Artemisinin Derivatives Artemisinin and semi-synthetic derivatives including dimers and trimers developed for antimalarial, antileukemia, and antiviral applications.
• Otviciclib (CDK Inhibitor) A first-in-class CDK inhibitor drug candidate co-developed with the Medical University of Innsbruck for multiple myeloma and solid tumors, targeting CDK1 (29nM), CDK2 (17nM), CDK3 (11nM), CDK5 (6nM), CDK9 (15nM), CDK16 (30nM), and WNT (10nM). Active in mouse models with oral bioavailability, induces caspase-dependent apoptosis, and synergizes with Bortezomib.
• VCC905240 A specific kinase inhibitor compound (C19H14Cl2N2O4, 493.61 g/mol) available in amounts up to 25g with approximately 30-day delivery time, supplied to research clients.
• Hit Finding, Assay Development & Screening High throughput screening service using IMAP technology, fluorescence polarization, and Transcreener Kinase Assay for kinase or non-kinase targets. Offered to pharmaceutical and biotech R&D teams.
• Hit-to-Lead Optimization, Patentable Lead Generation Medicinal chemistry lead generation and optimization services using in silico ADME filters, docking methods, and QSPR modeling to improve efficacy and ADMET properties, leveraging more than 27,000 synthetic protocols.
• Custom Synthesis Custom synthesis of complex heterocycles including reference compounds, metabolites, prodrugs, and compound libraries using traditional medicinal chemistry, Grignard reactions, metal-mediated coupling, and microwave-assisted synthesis up to 18 steps.
• Process Development & Optimization Scale-up services from mg to hundred-gram amounts of heterocyclic druglike molecules for preclinical development studies.
• Synthetic Chemistry Services for Target Identification Custom synthesis of potential drug molecules equipped with suitable linkers for target identification and binding affinity determination by affinity chromatography.
• Fluorescent Labeling of Small Molecules Fluorescent small molecule probe synthesis for binding kinetic studies, labeling kinase inhibitors and other small molecules with fluorescent dyes for client research programs.
• Analytical Services (NMR) NMR analytical services using a Bruker Avance 300 NMR spectrometer with full suite of NMR methods (1H, 13C, DEPT, COSY, TOCSY, NOESY, ROESY, HSQC, HMBC, HSQC-COSY, HSQC-TOCSY, HSQMBC, J-HMBC) for small molecules up to 1000 Da.

Quantifiable outcome

• NCL hit-rates consistently above 3-5% across kinase and cellular targets
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

17 partnerships are on record, tiered major and core.

• Indian Institute of SciencemajorStrategic or Co-development Partner · 1 November 2015Partner in the TET_13_DST Hungarian-Indian K+F+I cooperation program for new anti-tuberculosis drug development. IIS conducts cellular tuberculosis testing of compounds selected from Vichem's NCL library. Indian partner work is funded by DST.
• MTA Természettudományi Kutatóközpont (Hungarian Academy of Sciences)majorStrategic or Co-development Partner · 1 June 2013MTA TTK (Hungarian Academy of Sciences, Institute of Enzymology and other institutes) is a consortium partner in the KMR-12 project (kidney fibrosis) and the TET_13_DST project (tuberculosis), providing target identification and protein expression capabilities.
• Pharma-Trend Kft.majorStrategic or Co-development Partner · 1 June 2013Consortium partner in the KMR-12 project, responsible for kinase structure studies, protein production (Aurora kinase, ROCK-1), and recombinant protein expression with dual-tagged vectors.
• Max Planck Institute of BiochemistrycoreStrategic or Co-development PartnerVichem's most important strategic partner is the research institute of the Max Planck Society in Martinsried (Munich suburb). Vichem is developing several kinase inhibitors for numerous targets with this partner, representing a deep and long-standing strategic alliance in drug discovery.
• ViroStaticscoreStrategic or Co-development PartnerViroStatics is committed to discovering innovative, first-in-class disease-modifying medicines for viral infections, cancers, and inflammatory diseases. Vichem collaborates with ViroStatics on preclinical lead optimization for a novel anti-HIV drug (CDK9 inhibitors).
• Oncotyrol – Center for Personalized Cancer Medicine GmbHcoreStrategic or Co-development PartnerOncotyrol is the Austrian center for translational research in personalized cancer medicine. Vichem collaborates with Oncotyrol on three projects: multiple myeloma (FP7 OPTATIO), development of novel BRAF inhibitors, and cancer stem cell project.
• Lead Discovery Center GmbH (LDC)majorStrategic or Co-development PartnerLDC transforms innovative German biomedical basic research into pharmaceutical applications. Vichem collaborates with LDC in bridging academic findings to commercially viable products in drug discovery.
• Semmelweis UniversitycoreStrategic or Co-development PartnerSemmelweis University in Budapest, Hungary, has a long-standing collaboration with Vichem in kinase inhibitor research. Consortium partner in KMR-12 (kidney fibrosis project) and multiple FP7 projects. Includes participation from I. sz. Gyermekgyógyászati Klinika, SE Orvosi Vegytani, Molekuláris Biológiai és Patobiokémiai Intézet.
• EPFL (Cole Lab)majorStrategic or Co-development PartnerEPFL's Cole Lab focuses on tuberculosis and leprosy research using genome biology. Vichem collaborates with EPFL in the context of NM4TB (More Medicines for Tuberculosis) and other TB programs, applying kinase inhibitor expertise to mycobacterial targets.
• A*STAR (Agency for Science, Technology and Research)majorStrategic or Co-development PartnerSingapore's A*STAR fosters world-class scientific research and talent. Vichem collaborates with A*STAR on biomedical research leveraging Singapore's research infrastructure and Vichem's compound library expertise.
• Proteros biostructures GmbHmajorTechnology or IntegrationProteros is Europe's largest biotech in X-ray protein structure analysis. Vichem works with Proteros for Reporter Displacement Binding Assays and structural biology to determine binding types of kinase inhibitors, particularly for type II and III allosteric inhibitors.
• Medical University of InnsbruckcoreStrategic or Co-development PartnerVichem and Medical University of Innsbruck co-developed Otviciclib, a first-in-class CDK inhibitor for multiple myeloma and solid tumors. Innsbruck contributed phenotypic assay expertise and validated tumor microenvironment models.
• Institut Pasteur (Laboratory of Integrated Mycobacterial Pathogenomics)majorStrategic or Co-development PartnerListed as a partner; collaborates through MM4TB (More Medicines for Tuberculosis) and other TB drug development programs. The laboratory focuses on mycobacterial pathogenomics for TB drug discovery.
• Institut Pasteur (Laboratory of Structural Microbiology)majorStrategic or Co-development PartnerListed as a partner; structural microbiology collaboration for tuberculosis research within the NM4TB/MM4TB framework.
• KU Leuven (Laboratory of Protein Phosphorylation and Proteomics)majorStrategic or Co-development PartnerListed as a partner; collaboration involves protein phosphorylation and proteomics research, supporting kinase target validation.
• University of Amsterdam (Swammerdam Institute for Life Sciences, Bacterial Cell Biology)majorStrategic or Co-development PartnerListed as a partner; collaboration in bacterial cell biology supporting TB drug discovery programs.
• The Weizmann Institute of Science (Department of Biological Regulation)majorStrategic or Co-development PartnerListed as a partner; collaboration with Prof. Yossi Yarden's group in biological regulation research, supporting signal transduction and kinase biology studies.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Reaction Biology Corporation: US-based CRO specializing in kinase profiling, biochemical and cellular kinase assays, and custom compound screening — a direct functional peer in kinase-focused contract research services.
• Selvita S.A. Poland-based contract research organization offering medicinal chemistry, kinase biology, and drug discovery services with multiple internal programs — directly comparable in size, geography (Central Europe), and service offering to Vichem.
• Domainex Ltd: UK-based integrated drug discovery CRO offering medicinal chemistry, hit identification, and lead optimization services — a direct peer in fee-for-service small molecule drug discovery.
• Proteros biostructures GmbH: Germany-based structural biology and drug discovery CRO offering protein crystallography, biophysics, and kinase hit characterization — a direct peer in structure-enabled kinase drug discovery and an existing Vichem partner.

Broad incumbents

• ChemPartner: Shanghai-based integrated CRO offering medicinal chemistry, in vitro biology, DMPK and discovery services to global pharma — a broad incumbent peer competing for outsourced drug discovery programs.
• Evotec SE: Large Hamburg-based CRO with extensive kinase discovery platforms, compound libraries, and end-to-end drug discovery services — overlaps with Vichem's kinase and medicinal chemistry capabilities at much greater scale.
• Eurofins Discovery (Panlabs): Global CRO providing broad drug discovery services including kinase assays, medicinal chemistry, and in vitro pharmacology — competes in adjacent service lines but at much broader scale than Vichem.
• WuXi AppTec: China-headquartered global CRO/CDMO offering medicinal chemistry, kinase biology, and discovery services across all modalities — competes for the same pharma outsourcing wallets as Vichem at significantly larger scale.
• Charles River Laboratories, Inc. Global CRO with a Discovery and Safety Assessment segment offering medicinal chemistry, in vitro biology, and integrated discovery services — a broad incumbent competitor for outsourced pharma R&D.

Emerging players

• Sundia MediTech Co., Ltd. China-based CRO offering medicinal chemistry, custom synthesis, and biology services to pharma — an emerging peer with comparable CRO offerings and overlap with Vichem's custom synthesis and library services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/in/l%C3%A1szl%C3%B3-%C5%91rfi-57a7941

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vichem Chemie Research Ltd